Marín-Corte JC, Olmedo-Gutiérrez E, Marín-Corte JA, Miranda RN, Bueso-Ramos CE, Cano-Jiménez O, Fuentes-Reyes AR, Hernández-Salamanca E, López-Trujillo MA, Marín-López RA, Ruiz-Delgado GJ, Ruiz-Argüelles GJ

Language: English
References: 12
Page: 158-171
PDF size: 497.55 Kb.

ABSTRACT

Background: The myelodysplastic syndromes are one of the most studied diseases in hematology in recent years. By definition and according to the World Health Organization Classification of Tumours of hematopoietic and Lymphoid Tissues 2017, myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia, dysplasia in one or more of the major myeloid lineages, ineffective hematopoiesis, recurrent genetic abnormalities and increased risk of developing acute myeloid leukemia (AML). To identify in a quick way this disease, we designed a worksheet based on the article of Matteo Della-Porta et al to developed a systematic approach to assess the morphological features in the bone marrow smears of three cell lineages in patients with myelodysplastic syndromes and provide the basis to validate flow cytometric and immunohistochemistry data.
Clinical case: A 47-year-old male patient in whom we applied a worksheet that we designed based on Della-Porta score criteria to each cellularity lineage in the bone marrow smears and we obtained significant results according to the bone marrow biopsy final report.
Conclusions: If we apply the worksheet that we designed base on Della-Porta score in the bone marrow smears myelograms, we can identify in early stages myelodysplastic syndromes processes.

REFERENCES

1. Swerdlow SHC, Elias; Harris, Nancy Lee; . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. The International Agency for Research on Cancer 2017; 4th Edition: 1-482.

2. Della Porta MG. Prognostic models in myelodysplastic syndromes. The Lancet Haematology 2015; 2: e229-30. doi: 10.1016/S2352-3026(15)00110-6

3. Hidalgo-Lopez JE, Kanagal-Shamanna R, Quesada AE, et al. Progress in myelodysplastic syndromes: Clinicopathologic correlations and immune checkpoints. Clin Lymphoma Myeloma Leuk 2017; 17s: S16-s25. doi: 10.1016/j. clml.2017.02.022.

4. Society LaL. MDS Subtypes. Rye Brook, New York, United States 2019.

5. Bennett JM. Changes in the Updated 2016: WHO Classification of the myelodysplastic syndromes and related myeloid neoplasms. Clin Lymphoma Myeloma Leuk 2016; 16: 607-9. doi: 10.1016/j.clml.2016.08.005

6. Society LaL. The International Prognostic Scoring System. Rye Brook, New York, United States 2019.

7. Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromesproposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 2014; 28: 1793-8. doi: 10.1038/leu.2014.191

8. Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 2015; 29: 66-75. doi: 10.1038/leu.2014.161

9. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008; 93: 1712-7. doi: 10.3324/ haematol.13405

10. Kesbeh Y, Pakbaz Z. Pernicious anemia: a myelodysplastic syndrome look-alike. J Community Hosp Intern Med Perspect 2019; 9: 240-3. doi: 10.1080/20009666.2019.1622382

11. van den Berg H, Scherpbier HJ, Kroes W. Myelodysplastic syndrome in an HIV-1-infected infant. Med Pediatr Oncol 1999; 32: 385. https://doi.org/10.1002/(SICI)1096- 911X(199905)32:5%3C385::AID-MPO14%3E3.0.CO;2-R

12. Zeidan AM, Hu X, Zhu W, et al. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leuk Lymphoma 2019: 1-12. doi: 10.1080/10428194.2019.1663423